SPAS(SH:603168)2023-04-28 16:00Financial Performance - The company's operating revenue for Q1 2023 was ¥162,202,066.07, representing an increase of 8.59% compared to the same period last year[5]. - The net profit attributable to shareholders decreased by 18.54% to ¥22,525,376.46[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 104.03% to ¥24,301,318.63[5]. - Basic and diluted earnings per share were both ¥0.06, down by 32.81% year-on-year[5][9]. - Net profit for Q1 2023 was ¥22,376,182.97, down 19.1% from ¥27,651,872.01 in Q1 2022[31]. - Operating profit for Q1 2023 decreased to ¥31,393,451.39 from ¥36,000,436.05 in Q1 2022, reflecting a decline of 12.5%[30]. - Research and development expenses decreased significantly to ¥10,201,993.58, a reduction of 50.7% compared to ¥20,623,127.13 in Q1 2022[30]. - The company's net profit for the first quarter of 2023 is yet to be disclosed, but the financial report indicates ongoing investments in new projects and partnerships[29]. Cash Flow and Assets - The net cash flow from operating activities was negative at -¥7,024,659.27, a decrease of 122.98% compared to the previous year[5][9]. - Cash flow from operating activities turned negative at -¥7,024,659.27 in Q1 2023, compared to a positive ¥30,565,574.33 in Q1 2022[33]. - Cash and cash equivalents decreased to CNY 440,240,971.36 from CNY 525,059,148.89, reflecting a decline of approximately 16.2%[25]. - Cash and cash equivalents at the end of Q1 2023 were ¥440,240,971.36, down from ¥258,587,877.03 at the end of Q1 2022[34]. - Total assets at the end of the reporting period were ¥2,000,665,004.28, an increase of 2.20% from the end of the previous year[6]. - Total current assets amounted to ¥727,804,786.34 as of Q1 2023[37]. - The company's current assets decreased to CNY 648,181,628.65 from CNY 727,804,786.34, representing a decline of approximately 10.9%[25]. - Total non-current assets reached ¥1,229,873,493.93, resulting in total assets of ¥1,957,678,280.27[38]. Equity and Liabilities - Shareholders' equity attributable to the parent company was ¥1,729,209,109.40, up by 1.32% from the previous year[6]. - The total equity attributable to shareholders rose to CNY 1,729,209,109.40 from CNY 1,706,683,732.94, an increase of approximately 1.3%[27]. - The total liabilities of the company rose to CNY 261,604,227.24 from CNY 240,993,686.20, indicating an increase of about 8.3%[27]. - Total current liabilities were reported at ¥205,816,952.14, while total liabilities amounted to ¥240,993,686.20[38]. - The company's total liabilities increased by approximately 2.5% from the previous period[38]. Investments and Acquisitions - The company completed the acquisition of 100% equity of Qingdao Shikang for RMB 66.5 million, enhancing its competitiveness in the ophthalmology market[17]. - The company applied for a merger loan of RMB 29 million from Zhejiang Pinghu Rural Commercial Bank to optimize its financing structure for the acquisition of Qingdao Shikang[18]. - The company has invested CNY 60 million in Shenzhen Jiusongtangyuan Investment Center, representing a 6% stake in the total capital[20]. - An additional investment of CNY 10 million was made in Hangzhou Suyin Linzhuo Equity Investment Partnership, accounting for a 10% stake[22]. Legal Matters - The company is involved in a lawsuit regarding equity transfer disputes, with the court freezing 51% and 49% equity stakes held by the defendants in Jilin Hongjing Pharmaceutical Co., Ltd.[16]. - The company signed a contract for the sale of 100% equity of Qiangshen Pharmaceutical, with an outstanding payment of RMB 40.18 million and overdue penalty of RMB 10.39 million due from Yue's Pharmaceutical[14]. Future Outlook - The company plans to focus on new product development and market expansion strategies in the upcoming quarters[32]. - The company is actively advancing the consistency evaluation of Benzalkonium Chloride Eye Drops (Shapu Aisi) as per the requirements of the National Medical Products Administration and Zhejiang Provincial Medical Products Administration[13].